title: Alcohol and HER2 polymorphisms as risk factor for cardiotoxicity in breast cancer treated with trastuzumab.
abstract: BACKGROUND
  Trastuzumab has no major side-effects except the potential for cardiac toxicity. The main objective of this study was to evaluate the association between trastuzumab-associated cardiac toxicity and two potential risk factors: alcohol intake and HER2 polymorphisms.
  
  
  METHODS
  In a retrospective cohort study of 237 women with non-metastatic HER2-positive breast cancer treated with trastuzumab, traditional risk factors were assessed by review of medical records, alcohol use by an administered questionnaire to women (n=132), and HER2 polymorphisms (Ile655Val and Ala1170Pro) using TaqMan assays (n=73).
  
  
  RESULTS
  Association was observed between alcohol intake (10 drinks and more per week) during the trastuzumab treatment and cardiac toxicity (p=0.04). For polymorphisms, compared to Ile/Ile carriers, HER2 Ile/Val was associated with a higher risk of cardiac toxicity (p=0.02).
  
  
  CONCLUSIONS
  Heavy alcohol use during the course of trastuzumab treatment and the HER2 Ile/Val genotype may constitute risk factors for cardiac toxicity.
authors.affiliation: Oncology Axis, CHU of Quebec Research Center, Quebec City, QC, Canada. julie.lemieux@uresp.ulaval.ca
authors.forename: Julie
authors.initials: J
authors.lastname: Lemieux
authors.forename: Caroline
authors.initials: C
authors.lastname: Diorio
authors.forename: Marc-André
authors.initials: MA
authors.lastname: Côté
authors.forename: Louise
authors.initials: L
authors.lastname: Provencher
authors.forename: Frédéric
authors.initials: F
authors.lastname: Barabé
authors.forename: Simon
authors.initials: S
authors.lastname: Jacob
authors.forename: Christine
authors.initials: C
authors.lastname: St-Pierre
authors.forename: Eric
authors.initials: E
authors.lastname: Demers
authors.forename: Rosemarie
authors.initials: R
authors.lastname: Tremblay-Lemay
authors.forename: Corinne
authors.initials: C
authors.lastname: Nadeau-Larochelle
authors.forename: Annick
authors.initials: A
authors.lastname: Michaud
authors.forename: Christian
authors.initials: C
authors.lastname: Laflamme
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000428:Alcohol Drinking; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics; D054715:Cardiotoxins; D015331:Cohort Studies; D005260:Female; D018734:Genes, erbB-2; D005838:Genotype; D006321:Heart / Q000187:drug effects; D006331:Heart Diseases / Q000139:chemically induced*; D006333:Heart Failure / Q000139:chemically induced; D006801:Humans; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics / Q000378:metabolism; D012189:Retrospective Studies; D012307:Risk Factors; D011795:Surveys and Questionnaires; D000068878:Trastuzumab; D016277:Ventricular Function, Left / Q000187:drug effects
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D054715:Cardiotoxins; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C508053:ERBB2 protein, human
keywords: Alcohol; HER2 polymorphism; cardiac risk factors; trastuzumab